These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21458847)

  • 21. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
    Fiore MM; Mackie IM
    Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative human pharmacology of low molecular weight heparins.
    Harenberg J; Stehle G; Augustin J; Zimmermann R
    Semin Thromb Hemost; 1989 Oct; 15(4):414-23. PubMed ID: 2554502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP; Walenga JM; Hoppensteadt DA; Vandenberg C; Brubaker A; Adiguzel C; Bakhos M; Fareed J
    Semin Thromb Hemost; 2008 Feb; 34(1):74-85. PubMed ID: 18393144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New challenges for a second-generation low-molecular-weight heparin: focus on bemiparin.
    Martínez-González J; Rodríguez C
    Expert Rev Cardiovasc Ther; 2010 May; 8(5):625-34. PubMed ID: 20450295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose response relationships of anticoagulant activities after subcutaneous administration of two low molecular weight heparins in healthy individuals.
    Hellstern P; Kiehl R; von Blohn G; Köhler M; Meierhenrich U; Wenzel E
    Thromb Haemost; 1986 Oct; 56(2):225-8. PubMed ID: 3810557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis.
    Greaves M;
    Thromb Haemost; 2002 Jan; 87(1):163-4. PubMed ID: 11848446
    [No Abstract]   [Full Text] [Related]  

  • 29. Comparative pharmacodynamic time-course of bemiparin and enoxaparin in healthy volunteers.
    Antonijoan RM; Rico S; Martínez-González J; Borrell M; Valcarcel D; Fontcuberta J; Barbanoj MJ
    Int J Clin Pharmacol Ther; 2009 Dec; 47(12):726-32. PubMed ID: 19954711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma.
    Dempfle CE; Zharkowa U; Elmas E; Ahmad-Nejad P; Neumaier M; Borggrefe M
    Thromb Haemost; 2009 Nov; 102(5):1001-6. PubMed ID: 19888540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inter-individual variability of effect of 7 low molecular weight antithrombin-dependent anticoagulants studied in vitro with calibrated automated thrombography.
    Hacquard M; Perrin J; Lelievre N; Vigneron C; Lecompte T
    Thromb Res; 2011 Jan; 127(1):29-34. PubMed ID: 20850172
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low molecular weight heparin fractions. Comparative preclinical study of various parameters].
    Fareed J
    J Mal Vasc; 1987; 12 Suppl B():59-63. PubMed ID: 2834492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Future alternatives to heparin: low-molecular-weight heparin and hirudin.
    Donayre CE; Ouriel K; Rhee RY; Shortell CK
    J Vasc Surg; 1992 Apr; 15(4):675-82. PubMed ID: 1313932
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mode of action of heparin and related drugs.
    Hemker HC; Beguin S
    Semin Thromb Hemost; 1991; 17 Suppl 1():29-34. PubMed ID: 1648791
    [No Abstract]   [Full Text] [Related]  

  • 35. Is the inhibition of both clot-associated thrombin and factor Xa more clinically relevant than either one alone?
    Meddahi S; Samama MM
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):207-14. PubMed ID: 19657318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacological profile of reviparin-sodium.
    Hoppensteadt D; Jeske W; Fareed J
    Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S11-6. PubMed ID: 8180323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Human pharmacokinetics of low molecular weight heparins.
    Cornelli U; Fareed J
    Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecular-weight heparins upon the phases of thrombin generation.
    Gerotziafas GT; Petropoulou AD; Verdy E; Samama MM; Elalamy I
    J Thromb Haemost; 2007 May; 5(5):955-62. PubMed ID: 17461929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antithrombin and heparin cofactor II-mediated inactivation of alpha-thrombin by a synthetic, sulfated mannogalactan.
    Gracher AH; Cipriani TR; Carbonero ER; Gorin PA; Iacomini M
    Thromb Res; 2010 Sep; 126(3):e180-7. PubMed ID: 20553946
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological activity and safety of the subcutaneous administration of high doses of low molecular weight heparin for 8 days in human volunteers.
    Harenberg J; Giese C; Dempfle CE; Stehle G; Heene DL
    Thromb Haemost; 1989 Jun; 61(3):357-62. PubMed ID: 2552604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.